Glycation does not alter LDL-induced secretion of tissue plasminogen activator and plasminogen activator inhibitor-1 from human aortic endothelial cells

被引:6
作者
Klein, RL
Semler, AJ
Baynes, JW
Thorpe, SR
Lyons, TJ
Jenkins, AJ
机构
[1] Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA
[2] Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA
[3] Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA
[4] Univ Oklahoma, Hlth Sci Ctr, Endocrinol Sect, Oklahoma City, OK 73104 USA
[5] Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia
来源
MAILLARD REACTION: CHEMISTRY AT THE INTERFACE OF NUTRITION, AGING, AND DISEASE | 2005年 / 1043卷
关键词
fibrinolysis; lipoproteins; LDL; glycation; endothelial cells; tissue plasminogen activator; plasminogen activator inhibitor-1; LOW-DENSITY-LIPOPROTEIN; FIBRINOLYTIC REGULATORS; GENERATION;
D O I
10.1196/annals.1333.044
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Diabetes may induce both quantitative and qualitative changes in lipoproteins, especially low-density lipoprotein (LDL). Effects of LDL glycation on endothelial cell secretion of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) have not been fully elucidated. Human aortic endothelial cell (HAEC) tPA and PAI-1 production were determined after incubation with LDL (50 to 500 mu g/mL protein, 24 h) from three sources: (1) nondiabetic LDL (N-LDL) modified in vitro to form six preparations: native, nonmodified (N); glycated (G); minimally oxidized (MO); minimally oxidized and glycated (MOG); heavily oxidized (HO); and heavily oxidized and glycated (HOG); (2) in vivo glycated and relatively nonglycated LDL subfractions from type 1 diabetic patients; (3) LDL from type I diabetic patients and matched controls, which was subfractionated using density gradient ultracentrifugation. In experiments using LDL modified in vitro, the rate of tPA release by HAECs incubated with N-LDL (83 +/- 4 ng/mg cell protein/24 h) did not differ significantly from those incubated with G-LDL (73 7), MO-LDL (74 +/- 13), or MOG-LDL (66 +/- 15) and was not influenced by LDL concentration. The rate of PAI-1 release was similar in HAECs incubated with N-LDL (5.7 +/- 0.6 mu g/mg cell protein/24 h), G-LDL (5.7 +/- 0.7), MO-LDL (5.5 +/- 0.8), or MOG-LDL (5.7 +/- 0.9) and was not influenced by LDL concentration. In contrast, tPA release was significantly decreased in cells incubated with LDL (10 mu g/mL) modified extensively by oxidation, and averaged 45.2 +/- 5.0 and 43.7 +/- 9.9 ng/mg/24 h for HO-LDL and HOG-LDL, respectively, and was further decreased with increasing concentrations of the heavily oxidized LDL preparations. PAI-1 release was not significantly decreased relative to N-LDL in cells incubated with low concentrations (5 to 50 mu g/mL) of HO-LDL and HOG-LDL, but was decreased to 3.2 +/- 0.5 and 3.1 +/- 0.7 mu g/mg/24 h for HO-LDL and HOG-LDL at 200 mu g/mL, respectively. Results using in vivo glycated versus nonglycated LDL showed that tPA and PAI-1 release did not differ between subfractions. Release of tPA averaged 5.11 +/- 0.6 and 5.12 +/- 0.7 ng/mg/ 24 h, whereas release of PAI-1 averaged 666 +/- 27 ng/mg/24 h and 705 30 ng/ mg/24 h for nonglycated and glycated LDL subfractions, respectively. Using LDL of different density subclasses, tPA and PAI-1 release in response to LDL from diabetic patients compared with control subjects did not differ when HAECs were incubated with LDLs of increasing density isolated from each subject pair. We conclude that oxidation of LDL, but not glycation, may contribute to the altered fibrinolysis observed in diabetes.
引用
收藏
页码:379 / 389
页数:11
相关论文
共 13 条
[1]   'Lipoproteins, glycoxidation and diabetic angiopathy' [J].
Jenkins, AJ ;
Best, JD ;
Klein, RL ;
Lyons, TJ .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2004, 20 (05) :349-368
[2]   In vivo glycated low-density lipoprotein is not more susceptible to oxidation than nonglycated low-density lipoprotein in type 1 diabetes [J].
Jenkins, AJ ;
Thorpe, SR ;
Alderson, NL ;
Hermayer, KL ;
Lyons, TJ ;
King, LP ;
Chassereau, CN ;
Klein, RL .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2004, 53 (08) :969-976
[3]   Pre-enrichment of modified low density lipoproteins with α-tocopherol mitigates adverse effects on cultured retinal capillary cells [J].
Jenkins, AJ ;
Li, W ;
Moller, K ;
Klein, RL ;
Fu, MX ;
Baynes, JW ;
Thorpe, SR ;
Lyons, TJ .
CURRENT EYE RESEARCH, 1999, 19 (02) :137-145
[4]  
Jenkins AJ, 2003, CURR OPIN ENDOCRINOL, V10, P245
[5]  
KELLEY JL, 1986, METHOD ENZYMOL, V128, P170
[6]  
LopesVirella MF, 1996, DIABETES METAB REV, V12, P69, DOI 10.1002/(SICI)1099-0895(199603)12:1<69::AID-DMR156>3.0.CO
[7]  
2-B
[8]   Lipoprotein glycation and its metabolic consequences [J].
Lyons, TJ ;
Jenkins, AJ .
CURRENT OPINION IN LIPIDOLOGY, 1997, 8 (03) :174-180
[9]   GLYCOSYLATION OF LOW-DENSITY-LIPOPROTEIN IN PATIENTS WITH TYPE-1 (INSULIN-DEPENDENT) DIABETES - CORRELATIONS WITH OTHER PARAMETERS OF GLYCEMIC CONTROL [J].
LYONS, TJ ;
BAYNES, JW ;
PATRICK, JS ;
COLWELL, JA ;
LOPESVIRELLA, MF .
DIABETOLOGIA, 1986, 29 (10) :685-689
[10]   Impaired endogenous fibrinolysis in diabetes mellitus: Mechanisms and therapeutic approaches [J].
Nordt, TK ;
Bode, C .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2000, 26 (05) :495-501